 Bone mass endometriosis patients GnRH agonist implant danazol treatment trabecular bone mineral content lumbar spine femoral neck different endometriosis patients age-matched controls subjects monthly goserelin implant serum estradiol levels menopausal range Mean decreases pre-treatment values lumbar spine femoral neck months months treatment values different control group values little period Significant increases baseline values urinary calcium-creatinine ratio serum alkaline phosphatase danazol-treated subjects levels early follicular-phase range significant changes bone assessments Normal menses months cessation medication Six months goserelin treatment lumbar spine femoral neck bone mineral content values different pre-treatment control values urinary calcium-creatinine ratio whereas serum alkaline phosphatase rapid deep suppression ovarian steroidogenesis monthly goserelin implant significant bone loss control danazol groups loss months cessation treatment bone densities time different controls Studies numbers patients periods question complete reversibility